Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Head-Mounted heat device boost brain function in Alzheimer's?

NCT ID NCT07672171

Symptom relief Sponsor: Juin-Hong Cherng Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a head-mounted far-infrared therapy device in 40 people with mild-to-moderate Alzheimer's disease. The device is placed on specific points on the head and delivers gentle heat. Researchers will check if it is safe and whether it helps improve cognitive function, such as memory and thinking. The goal is to find a non-drug way to support brain health and reduce caregiver burden.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
far-infrared therapy device
What this could lead to
If it works, this could offer a safe, non-drug option to help slow cognitive decline in Alzheimer's disease.
What could go wrong
This is a small, early-stage trial with only 40 participants. The device may not improve cognition, and results may not apply to all dementia patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2022

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

61 to 92 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosed with Alzheimer's disease dementia. 2. Mini-Mental State Examination (MMSE) score between 18 and 24 (inclusive). 3. Currently prescribed and maintained on a stable regimen of anti-dementia medication. 4. No sensory deficits or impairment regarding skin temperature perception. 5. Patient or a Legally Authorized Representative (LAR) must be willing and capable of providing written informed consent prior to enrollment. Exclusion Criteria: 1. Non-Alzheimer's disease dementia (e.g., vascular dementia, Lewy body dementia, frontotemporal dementia). 2. Known hypersensitivity to heat or light, including the current use of photosensitizing medications. 3. Diminished thermal or heat sensitivity, such as from the concurrent use of analgesics, sedatives, or consumption of alcoholic beverages. 4. Acute injury or acute localized inflammation, including active inflammation, infection, or ulcerated wounds. 5. Concomitant acute venous thrombosis, varicose veins, severe peripheral arterial occlusive disease (Stage III or IV), lymphatic disease, acute rheumatoid arthritis, acute gout, or active fever. 6. Presence of mottled erythema or other abnormal dermatological conditions on the scalp or neck. 7. Localized skin lesions, damage, or open wounds at the device contact sites. 8. Concurrent participation in any other clinical trial. 9. Any other underlying pathological conditions or clinical statuses that, based on medical consensus, would preclude safe participation in the study. 10. Failure or refusal to provide signed informed consent. 11. Inability or unwillingness to comply with the trial protocols, schedules, or required follow-up evaluations. 12. History or presence of hemorrhagic disorders or bleeding-related diseases.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Dementia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Trial-Service General Hospital, National Defense Medical University

    RECRUITING

    Taipei, 11490, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.